Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...

Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...

Equities researchers at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Thursday, March 13th. HC Wainwright ...

Nektar Therapeutics (NKTR) came out with quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial ... First, we continue to advance our novel TNFR2 agonist antibody program, NKTR-0165. IND-enabling studies are ongoing with ...